DifGen Pharmaceuticals
Private Company
Funding information not available
Overview
Founded in 2016, DifGen Pharmaceuticals has rapidly evolved into a full-service pharmaceutical value chain provider, combining expertise in complex generic drug development with advanced drug delivery technologies. Its strategic acquisition of Aveva Drug Delivery Systems Inc. in 2023 significantly bolstered its capabilities in transdermal and film-based delivery, making it a notable player in the affordable medicines and drug delivery sectors. The company is privately held, operates globally, and focuses on driving growth through operational excellence, regulatory expertise, and a diverse portfolio spanning all major dosage forms.
Technology Platform
Integrated platform for complex generic drug development and advanced drug delivery systems, specializing in transdermal patches and dissolvable oral films.
Opportunities
Risk Factors
Competitive Landscape
DifGen competes with large generic pharmaceutical companies (e.g., Teva, Viatris), specialized drug delivery firms, and contract development and manufacturing organizations (CDMOs). Its differentiation lies in combining complex generic expertise with scaled, advanced delivery system manufacturing in a vertically integrated service model.